{"DataElement":{"publicId":"6776725","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Cell-of-Origin Assay Outcome Type","preferredDefinition":"Information related to the outcome of the kind of cell associated with the origin of diffuse large b-cell lymphoma.","longName":"6776723v1.0:6776724v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6776723","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Cell-of-Origin Assay Outcome","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma._An assay that utilizes gene expression profiling of RNA extracted from formalin-fixed, paraffin-embedded tissue biopsies, in order to determine the cell of origin of the tumor._The result of an action.","longName":"2478319v1.0:6776721v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2478319","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003","longName":"C8851","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11E01CB8-267E-253F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-20","modifiedBy":"ONEDATA","dateModified":"2006-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6776721","version":"1","preferredName":"Cell-of-Origin Assay Outcome","preferredDefinition":"An assay that utilizes gene expression profiling of RNA extracted from formalin-fixed, paraffin-embedded tissue biopsies, in order to determine the cell of origin of the tumor.:The result of an action.","longName":"C158248:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cell-of-Origin Assay","conceptCode":"C158248","definition":"An assay that utilizes gene expression profiling of RNA extracted from formalin-fixed, paraffin-embedded tissue biopsies, in order to determine the cell of origin of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AF7A365-C701-1C56-E053-F662850AEA34","latestVersionIndicator":"Yes","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"ONEDATA","dateModified":"2019-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AF7A365-C712-1C56-E053-F662850AEA34","latestVersionIndicator":"Yes","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6776724","version":"1","preferredName":"Diffuse Large B-Cell lymphoma Cell Of Origin Type","preferredDefinition":"The kind of cell associated with the origin of diffuse large b-cell lymphoma.","longName":"6776724v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Non-GCB","valueDescription":"Activated B-Cell-Like Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3185301","version":"1","preferredName":"Non-GCB","longName":"3185301v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Activated B-Cell Type","conceptCode":"C36081","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes.  Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1).  Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal center B-cell expression profile, with a 5-year survival rate of 35% and a median survival of 2 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F00-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AF52FBA-D717-1C62-E053-F662850ADC4F","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"ONEDATA","dateModified":"2019-06-10","deletedIndicator":"No"},{"value":"GCB","valueDescription":"Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"3185303","version":"1","preferredName":"GCB","longName":"3185303v1.00","preferredDefinition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","conceptCode":"C36080","definition":"A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile.  It represents approximately 50% of diffuse large B-cell lymphomas, and is characterized by the expression of CD10, BCL-6, A-myb, and LMO2 genes, BCL-2 translocation, and c-REL amplification.  Morphologically, the vast majority of these lymphomas are centroblastic and a small minority are immunoblastic (ratio20:1).  Patients with this type of diffuse large B-cell lymphoma have a more favorable outcome, with a 5-year survival rate of 60% and a median survival of 10 years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A602691-7F26-B189-E040-BB89AD437FA7","latestVersionIndicator":"Yes","beginDate":"2011-01-21","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-21","modifiedBy":"FINCHAMB","dateModified":"2023-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AF52FBA-D721-1C62-E053-F662850ADC4F","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"ONEDATA","dateModified":"2019-06-10","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8AF52FBA-D72B-1C62-E053-F662850ADC4F","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"ONEDATA","dateModified":"2019-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AF52FBA-D6F7-1C62-E053-F662850ADC4F","latestVersionIndicator":"Yes","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Cell of origin","type":"Preferred Question Text","description":"Cell of origin","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8AF80498-8462-1C42-E053-F662850A370B","latestVersionIndicator":"Yes","beginDate":"2019-06-10","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-10","modifiedBy":"MORENOC","dateModified":"2019-11-07","changeDescription":"11/7/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}